Login
Companies $OMER
$15.35 -$1.33 (8.0%) After hours
OMEROS CORP logo

OMEROS CORP

omeros.com

What Do They Do?

Sells YARTEMLEA, a treatment for a transplant complication, to transplant centers and develops medicines for complement-related diseases.

How Do They Make Money?

Omeros sells YARTEMLEA in the U.S.; for zaltenibart rights, it received an upfront payment at closing and may receive milestone payments when development, approval, or sales milestones are met, plus royalties on annual net sales.

FY2024 revenue

Who Are Their Customers?

Omeros’s U.S. team engages directly with transplant centers about YARTEMLEA and works with third-party payers on reimbursement. For sales outside the U.S., it is evaluating broader or regional partnerships.

Do Revenues Turn Into Profits?

No. It lost $156.8M in FY2024.

Operating income, FY2024
−1477% of revenue
▼ −1% (Loss) vs FY2023 (−$164.5M, −1007%)
Net income, FY2024
−1387% of revenue
▼ −33% (Loss) vs FY2023 (−$117.8M, −721%)
Free cash flow, FY2024
−1318% of revenue
▼ Turned to a loss vs FY2023 ($74.3M, 455%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Revenue
vs $0 in Q2 FY2025
Net income
▲ Turned profitable
vs −$25.4M in Q2 FY2025

Growing. Revenue grew 17.3x in 4 years, from $654K in FY2020 to $11.3M in FY2024, about 104% a year.

From development to sales Earlier, narsoplimab was still under development and its approval was unresolved; the latest report describes YARTEMLEA as an approved, commercially sold treatment for a complication of stem-cell transplantation.

Zaltenibart rights transferred Zaltenibart moved from Omeros’s clinical pipeline to Novo Nordisk’s development and commercialization rights; Omeros retained its unrelated small-molecule program.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support